Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-348 open-label extension study in adults with pyruvate kinase deficiency
2018-003459-39Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mitapivat in pyruvate kinase deficiency (PKD), sponsored by Agios Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Started Nov 2018; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on 2018-003459-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003459-39.